SCHEMBL183875

SCHEMBL183875

O=C(CI)Nc1cccc2c1C(=O)OC21c2ccc(O)cc2Oc2cc(O)ccc21

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FTO Q9C0B1 10/20 0.52
MAPT P10636 3/20 0.52
HPGD P15428 2/20 0.52
MEN1 O00255 2/20 0.52
HTT P42858 2/20 0.52
KMT2A Q03164 2/20 0.52
TDP1 Q9NUW8 2/20 0.52
CYP2C19 P33261 1/20 0.52
RECQL P46063 1/20 0.52
BLM P54132 1/20 0.52
SMAD3 P84022 1/20 0.52
PRMT1 Q99873 1/20 0.52
ACE2 Q9BYF1 1/20 0.52
ALDH1A1 P00352 2/20 0.50
ALOX12 P18054 2/20 0.50
CYP2C9 P11712 1/20 0.50
ALOX15 P16050 1/20 0.50
BRCA1 P38398 1/20 0.50
HSD17B10 Q99714 1/20 0.50
LMNA P02545 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1978381 0.89 FTO (0.52) FTOMAPTHPGDMEN1HTT
SCHEMBL7646663 0.89 FTO (0.52) FTOMAPTHPGDMEN1HTT
SCHEMBL11310755 0.89 FTO (0.52) FTOMAPTHPGDMEN1HTT
SCHEMBL1254421 0.88 FTO (0.64) FTOMAPTHPGDMEN1HTT
SCHEMBL5149281 0.88 FTO (0.55) FTOMAPTHPGDMEN1HTT
SCHEMBL9428188 0.86 FTO (0.56) FTOMAPTHPGDMEN1HTT
SCHEMBL9350491 0.86 FTO (0.47) FTOMAPTHPGDMEN1HTT
SCHEMBL9427469 0.85 HPGD (0.56) FTOMAPTHPGDMEN1HTT
SCHEMBL15778575 0.84 FTO (0.47) FTOMAPTHPGDMEN1HTT
SCHEMBL905219 0.84 FTO (0.47) FTOMAPTHPGDMEN1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1022 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2007122602-A1 A METHOD AND SYSTEM FOR MEASURING MEMBRANE POTENTIAL BASED ON FLUORESCENCE POLARIZATION SENG ENTERPRISES LTD. (CY) 2007-11-01 WO claimed
US-20070254276-A1 Method and system for measuring membrane potential based on fluorescence polarization SENG ENTERPRISES LTD. (CY) 2007-11-01 US claimed
US-6794158-B2 FLUORESCENT PROBE FOR USE AS DIAGNOSTIC TOOL IN MONITORING PREFERENTIAL ENZYME ACTIVITY BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. 2004-09-21 US claimed
US-20030082665-A1 Fluorescence polarization assay BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. 2003-05-01 US claimed
WO-2002082082-A2 FLUORESCENCE POLARIZATION ASSAY BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 2002-10-17 WO claimed
EP-0702689-A4 HAPTENS, TRACERS, IMMUNOGENS AND ANTIBODIES FOR 3-PHENYL-1-ADAMANTANEACETIC ACIDS ABBOTT LAB (US) 1997-10-22 EP claimed
EP-0708767-A4 HAPTENS, TRACERS, IMMUNOGENS AND ANTIBODIES FOR CARBAZOLE AND DIBENZOFURAN DERIVATIVES ABBOTT LAB (US) 1996-10-02 EP claimed
EP-0708767-A1 HAPTENS, TRACERS, IMMUNOGENS AND ANTIBODIES FOR CARBAZOLE AND DIBENZOFURAN DERIVATIVES ABBOTT LABORATORIES (US) 1996-05-01 EP claimed
EP-0702689-A1 HAPTENS, TRACERS, IMMUNOGENS AND ANTIBODIES FOR 3-PHENYL-1-ADAMANTANEACETIC ACIDS ABBOTT LABORATORIES (US) 1996-03-27 EP claimed
US-5424414-A Haptens, tracers, immunogens and antibodies for 3-phenyl-1-adamantaneacetic acids ABBOTT LABORATORIES (US) 1995-06-13 US claimed
WO-1995003296-A1 HAPTENS, TRACERS, IMMUNOGENS AND ANTIBODIES FOR CARBAZOLE AND DIBENZOFURAN DERIVATIVES ABBOTT LABORATORIES (US) 1995-02-02 WO claimed
WO-1994029329-A1 HAPTENS, TRACERS, IMMUNOGENS AND ANTIBODIES FOR 3-PHENYL-1-ADAMANTANEACETIC ACIDS ABBOTT LABORATORIES (US) 1994-12-22 WO claimed
WO-1993020074-A1 HAPTENS, TRACERS, IMMUNOGENS AND ANTIBODIES FOR ACRIDINE-9-CARBOXYLIC ACIDS ABBOTT LABORATORIES (US) 1993-10-14 WO claimed
WO-1993020094-A1 HAPTENS, TRACERS, IMMUNOGENS AND ANTIBODIES FOR QUINOLINE ABBOTT LABORATORIES (US) 1993-10-14 WO claimed
US-5145790-A Immunoassay, fluorescein derivative ABBOTT LABORATORIES (US) 1992-09-08 US claimed
EP-0455058-A2 Reagents and method for detecting polychlorinated biphenyls ABBOTT LABORATORIES (US) 1991-11-06 EP claimed
US-20260140105-A1 METHODS AND SYSTEMS FOR ANALYTE DETECTION AND ANALYSIS ULTIMA GENOMICS INC (US) 2026-05-21 US disclosed
US-20260132459-A1 COMPOSITIONS AND METHODS FOR PREPARING NUCLEIC ACID NANOSTRUCTURES USING COMPACTION OLIGONUCLEOTIDES ELEMENT BIOSCIENCES INC (US) 2026-05-14 US disclosed
EP-0199042-A1 Procainamide assay, tracers, immunogens and antibodies ABBOTT LABORATORIES (US) 1986-10-29 EP disclosed
EP-0194352-A2 Salicylate assay, tracers, immunogens and antibodies ABBOTT LABORATORIES (US) 1986-09-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260140105-A1 METHODS AND SYSTEMS FOR ANALYTE DETECTION AND ANALYSIS SRMS, CFD, STUB1 FTO 1073/4885MAPT 915/4885HPGD 4225/4885
US-20260132459-A1 COMPOSITIONS AND METHODS FOR PREPARING NUCLEIC ACID NANOSTRUCTURES USING COMPACTION OLIGONUCLEOTIDES PCNA, POLM, RNGTT FTO 2315/4885MAPT 4008/4885HPGD 4842/4885
US-20030082665-A1 Fluorescence polarization assay EPHX1, EPHX2, LTA4H FTO 539/4885MAPT 4854/4885HPGD 127/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.